Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

Apostolia Maria Tsimberidou; Elihu Estey; Gary J. Whitman; Mark J. Dryden; Suresh Ratnam; Sherry Pierce; Stefan Faderl; Francis Giles; Hagop M. Kantarjian; Guillermo Garcia-Manero

doi:10.1016/j.leukres.2004.01.004

Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

Apostolia Maria Tsimberidou, Elihu Estey, Gary J. Whitman, Mark J. Dryden, Suresh Ratnam, Sherry Pierce, Stefan Faderl, Francis Giles, Hagop M. Kantarjian, Guillermo Garcia-Manero^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A₂O₃, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.

Original language	English (US)
Pages (from-to)	991-994
Number of pages	4
Journal	Leukemia Research
Volume	28
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2004.01.004
State	Published - Sep 2004

Keywords

APL
ATRA
Extramedullary relapse

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2004.01.004

Cite this

Tsimberidou, A. M., Estey, E., Whitman, G. J., Dryden, M. J., Ratnam, S., Pierce, S., Faderl, S., Giles, F., Kantarjian, H. M., & Garcia-Manero, G. (2004). Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leukemia Research, 28(9), 991-994. https://doi.org/10.1016/j.leukres.2004.01.004

@article{6e12d48150324a498b28d271cd1cc5a6,

title = "Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies",

abstract = "Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.",

keywords = "APL, ATRA, Extramedullary relapse",

author = "Tsimberidou, {Apostolia Maria} and Elihu Estey and Whitman, {Gary J.} and Dryden, {Mark J.} and Suresh Ratnam and Sherry Pierce and Stefan Faderl and Francis Giles and Kantarjian, {Hagop M.} and Guillermo Garcia-Manero",

year = "2004",

month = sep,

doi = "10.1016/j.leukres.2004.01.004",

language = "English (US)",

volume = "28",

pages = "991--994",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "9",

}

Tsimberidou, AM, Estey, E, Whitman, GJ, Dryden, MJ, Ratnam, S, Pierce, S, Faderl, S, Giles, F, Kantarjian, HM & Garcia-Manero, G 2004, 'Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies', Leukemia Research, vol. 28, no. 9, pp. 991-994. https://doi.org/10.1016/j.leukres.2004.01.004

Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. / Tsimberidou, Apostolia Maria; Estey, Elihu; Whitman, Gary J. et al.
In: Leukemia Research, Vol. 28, No. 9, 09.2004, p. 991-994.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Extramedullary relapse in a patient with acute promyelocytic leukemia

T2 - Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

AU - Tsimberidou, Apostolia Maria

AU - Estey, Elihu

AU - Whitman, Gary J.

AU - Dryden, Mark J.

AU - Ratnam, Suresh

AU - Pierce, Sherry

AU - Faderl, Stefan

AU - Giles, Francis

AU - Kantarjian, Hagop M.

AU - Garcia-Manero, Guillermo

PY - 2004/9

Y1 - 2004/9

N2 - Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.

AB - Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.

KW - APL

KW - ATRA

KW - Extramedullary relapse

UR - http://www.scopus.com/inward/record.url?scp=3242711151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242711151&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.01.004

DO - 10.1016/j.leukres.2004.01.004

M3 - Article

C2 - 15234578

AN - SCOPUS:3242711151

SN - 0145-2126

VL - 28

SP - 991

EP - 994

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this